Novartis in Slovenia once again invites students to participate in the BioCamp, this time with a focus on data and artificial intelligence
- For eleven years, Novartis in Slovenia has been providing a unique insight into the world of research and the international business environment of the pharmaceutical industry.
- The BioCamp is an awarded scientific event for students of natural, economic and technical sciences, designed to connect with renowned experts and top managers.
- The virtual BioCamp 2021 will take place between September 27 and October 1, applications are open until May 31. The central theme will be the impact of data and artificial intelligence on the pharmaceutical industry.
In the autumn, Novartis in Slovenia will once again organize the BioCamp, a scientific event intended to bring together top students, academia and industry. The award-winning HR practice offers young people from all over the world a unique insight into the pharmaceutical industry and guides them on their path from young professionals to future leaders. »The BioCamp is an established project in which we combine some of our strategic orientations, innovation support, care for the development of young professionals and the integration of the economic and academic spheres. Since the event takes place online, we can accept students from outside our region and expand our reach to young talents. Through several days of networking and facing the real challenges of the pharmaceutical industry, participants also learn about our core values, as we encourage them to be innovative, curious and work as a team in finding a solution,« said Janko Ignjatović, Head of Development Projects at the Development Center Slovenia andChair of the BioCamp Organizing Committee.
Through lectures by top experts, the participants of the 11th BioCamp will learn how science, entrepreneurship and technology combine to benefit the patient. They will have the opportunity to get together with leading experts, managers and students from other countries and as a team, solve and design business solutions to existing challenges in the pharmaceutical industry. During the five-day event, they will also get to know Novartis in Slovenia and career opportunities in one of the leading pharmaceutical companies in the world. »The experience I gained by participating in the regional BioCamp at the end of my studies has uniquely contributed to my personal growth, both as a future scientist and expert. I got to know the dynamic and globalized business environment of the pharmaceutical and biotechnology industry and had the opportunity to connect with key experts from industry and academia. Immediately after finishing the BioCamp, I was offered the opportunity of a scientific exchange at the Sandoz Development Center in Ljubljana, where I am currently starting my career as a scientist in pharmaceutical development,« said former BioCamp participant Ognen Jakasanovski, researcher at the Development Center.
At last year’s International Conference on the Development of Organizational Sciences, the BioCamp event received the award for best HR practice 2020 - an honorable mention. Over the last ten years, 357 young people from 31 countries participated in the BioCamp of which more than 45 are now employed at Novartis. Every year, future scientists deal with topical issues in the pharmaceutical industry, this year they will focus on data and artificial intelligence. Registration for the event is open until May 31 at www.lek.si/biocamp. For further information, visit www.lek.si/biocamp.
Novartis is the leading provider of medicines in Slovenia, where Lek d.d., Novartis Pharma Services Inc., Podružnica v Sloveniji and Sandoz d.d., operate. Together we are building and maintaining the reputation of a dynamic, ethical, and trusted pharmaceutical company. Lek develops, manufactures, and markets effective, safe, and high quality medicines and active pharmaceutical ingredients. With our knowledge, quality, and experience we have gained an important role in Novartis' organizational structure, especially in the Novartis Technical Operations, Global Drug Development, Novartis Business Services, and the generic division Sandoz. We are the leading Sandoz development center, and one of the key development sites for technologically complex projects. We invest a great deal in the development, education, and training of our employees. Over the last nine years, the company has created more than 3,350 new job opportunities, making us one of the biggest employers in Slovenia. Novartis invested in Slovenia more than EUR 2.7 billion since 2003.
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2020 sales of USD 9.6 billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.
Sandoz is on Twitter. Sign up to follow @SandozGlobal at http://twitter.com/Sandoz_Global.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Communications & External Engagement
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43